And it was differentially expressed in five immune subtypes (previous research suggested that six immune subtypes could be identified in tumors, and there were significant differences in immune infiltration and sensitivity to immunotherapy among subtypes, five immune subtypes could be identified in BC) [34], implying that HDAC9 could be used to classify immune subtypes, which would help individualized treatment. Here, HDAC9 is linked to breast cancer.